Broking Break - Your Top 5

five-5-stars

The Gallagher vs. Ardonagh trial has borne several highly read stories this week with acquisitions and people moves also catching the interest of Insurance Age readers.

5. Marsh-owner gains approval to buy Jardine Lloyd Thompson 

Marsh & McLennan’s deal to buy JLT has received regulatory approval from the European Commission. The acquisition will cost around £4.6bn and a hearing to gain UK High Court approval is set for today (29 March).

If the court support the purchase it is anticipated to close on 1 April.

MMC originally agreed to buy the broker back in September, but the European Commission raised some concerns about the

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@insuranceage.co.uk.

You are currently unable to copy this content. Please contact info@insuranceage.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Age? View our subscription options

Register

Sign up and gain access to five complimentary news articles every month.

Already have an account? Sign in here

This address will be used to create your account

Meet the MGA: Kayzen Specialty

Kayzen Specialty founder and CEO Charles Boorman explains to Jonathan Swift his plans for the MGA to be a go-to market for financial lines through continuous improvement across its three pillars of broker-centric, underwriter-fronted and tech-focused.

i-Wonder delivers on fast food

i-Wonder, provider of niche insurance comparison website solutions, has confirmed the adoption of its offering for the UK fast food delivery sector by “one of” the UK’s main aggregators, Insurance Age can reveal.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Age account, please register now.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: